Original Research
Published on 21 Oct 2022
Humoral and cellular immune responses to CoronaVac up to one year after vaccination
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1032411
- 5,783 views
- 12 citations
Type at least 3 characters
2,749 articles
Articles
Original Research
Published on 21 Oct 2022
Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1027180
- 2,469 views
- 3 citations
Correction
Published on 21 Oct 2022
Corrigendum: Co-stimulation with TLR7 agonist imiquimod and inactivated Influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1053779
- 1,022 views
Mini Review
Published on 20 Oct 2022
The lymphatic system and COVID-19 vaccines
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1041025
- 7,480 views
- 8 citations
Original Research
Published on 20 Oct 2022
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.965550
- 2,225 views
- 1 citation
Original Research
Published on 20 Oct 2022
Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.982196
- 2,351 views
- 6 citations
Original Research
Published on 19 Oct 2022
Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on ClinicalTrials.gov
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.936667
- 2,823 views
- 3 citations
Review
Published on 17 Oct 2022
Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs– focus on the bigger picture
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1025884
- 20,540 views
- 7 citations
Original Research
Published on 17 Oct 2022
Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.988304
- 1,844 views
- 8 citations
Original Research
Published on 14 Oct 2022
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.983000
- 19,011 views
- 34 citations
Brief Research Report
Published on 13 Oct 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1016927
- 5,934 views
- 9 citations
Original Research
Published on 13 Oct 2022
Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1004804
- 12,877 views
- 25 citations
Review
Published on 12 Oct 2022
Advances in immunotherapy for glioblastoma multiforme
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.944452
- 15,217 views
- 48 citations
Brief Research Report
Published on 12 Oct 2022
Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1001951
- 2,245 views
- 4 citations
Original Research
Published on 12 Oct 2022
Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.983313
- 2,202 views
- 5 citations
Original Research
Published on 11 Oct 2022
Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2022.1018393
- 3,757 views
- 15 citations